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dard OS extrapolation methods which fit ‘traditional’ parametric survival
distributions to patient-level data, two different methods were explored in the
modelling of OS beyond the trial duration (55 months) for the novel immunother-
apy ipilimumab. In the first approach, the hazard rate from the Kaplan-Meier (KM)
curve between 24 and 36 months (before reaching a plateau) was used to extend the
curve. In the second approach, different parametric curves were fitted to the period
of 18 months onwards. Akaike’s Information Criterion (AIC) was used to determine
the best fit curve. RESULTS: When compared to standard OS extrapolation meth-
ods, both methods exhibited a better visual fit to the data. Both approaches allow
the hazard of the extrapolated tail to be based on a section of the KM curve that is
more appropriate in describing the long-term survival of these patients. The haz-
ard rate approach does not allow for a formal comparison with AIC, but allows
extrapolation in line with the clinical interpretation. The ‘parametric curves’ ap-
proach allows for a statistically better fit with the patient level data using conven-
tional AIC criteria. Both methods are in line with long-term observations of immu-
notherapy.CONCLUSION: For novel cancer therapies whose KM curves are not well
described by standard survival distributions, other methods of extrapolation
should be explored in conjunction with an understanding of the clinical rationale.
In this case study, two alternatives are presented that describe the OS of immuno-
therapy patients in a more suitable way.
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OBJECTIVES: Conventional economic evaluation involves piecewise comparisons
of competing interventions at a single point in a broader care pathway.METHODS:
This approach is subject to several problems: a) there remains an ongoing debate
surrounding the appropriateness of threshold-based decision rules and whether
their repeated use will maximise health; b) restricting the model scope to a single
decision point means that other adoption decisions elsewhere in the disease path-
way may be treated as independent of the problem under consideration; and c) the
absence of model development guidance leads to inconsistencies between analy-
ses addressing similar decision problems. In light of these problems, this study
puts forward the notion of “Whole Disease Modelling.” This involves simulating
whole disease and treatment pathways within a single model, from preclinical
disease through to diagnosis and referral, adjuvant treatment, follow-up, potential
recurrence, palliative treatment, end-of-life care and eventual death. A method-
ological framework has been developed based on three key principles: 1) the model
boundary and breadth should capture all relevant aspects of the disease and its
treatment; 2) the model should be developed such that the decision node is con-
ceptually transferable across the pathway; and 3) the costs and consequences of
service elements should be structurally related. RESULTS: Case study applications
in colorectal cancer services suggest that Whole Disease Modelling is feasible and
may provide a consistent platform for economic analysis at virtually any point in a
disease pathway using multiple economic decision rules. CONCLUSIONS: The
value of the approach may be realised when: multiple decision problems require
formal economic analysis at a single timepoint; services are subject to rapid inno-
vation and the model can be re-used; a substantial proportion of currently provided
service elements have not previously been subjected to economic analysis, and;
standard cost-utility decision rules fail to reflect the complexity of the decision-
makers’ objectives.
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OBJECTIVES: The aim of this study was to investigate whether broadening the
evaluative space in an economic evaluation would lead to other outcomes, and
hence policy recommendations. METHODS: Two discrete choice experiments
(DCE) were conducted in a population of patients who had been treated for varicose
vein disease (N390) either by foam sclerotherapy or surgical stripping. In the
Health DCE the treatments were described in terms of health outcomes attributes
only (based on the EQ5D dimensions). In the Extended DCE the treatments were
described in terms of the same health outcomes attributes and other aspects (Wait-
ing time, Probability of retreatment and Nature of treatment). The differences in
the levels were collected in a clinical trial and entered into the preference models
to calculate the differnce in utility between those treatments. The 	U in both
models was standardised on a [-1,1] scale. The incremental costs of foamsclero-
therapy versus surgical stripping, as observed in the clinical trial, amounted to
-€1123. RESULTS: All attributes were statistically significant, except for Waiting
time and Probability of retreatment. The relative importances and the ranks of the
health attributes differed between the models. The patients preferred surgical
treatment if only health outcomes were considered, while the patients preferred
dermatological treatment if also aspects beyond health outcomes were considered
in the choice: 	Uhealth-0.0109; 	Uextended0.3971. When incremental utility
was based on health outcomes only alone, the incremental cost-utility ratio was
€103,027. When incremental utility was based broader outcomes, the incremental
utility ratio indicated dominance. CONCLUSIONS: The results suggest that recom-
mendation for policy would changed if not only health outcomes but also broader
outcomes are considered. The results confirm that a restriction to health outcomes
in the (economic) evaluation of health care leads to the maximization of health, but
not necessarily to the maximization of benefit in a broader sense.
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OBJECTIVES: To identify existing knowledge about the costs and benefits, assessed
either quantitatively or qualitatively, of performance based reimbursement, risk
sharing schemes, patient access schemes, and flexible pricing schemes for
pharmaceuticals. METHODS: A systematic literature review was conducted using
PubMed for the period January 2008 - April 2011. The terms “risk sharing”, “flexible
pricing”, “patient access schemes”, and “performance-based reimbursement” were
searched in titles and abstracts.RESULTS:The search provided 62 records and after
screening the number was reduced to 31. After full assessments of these studies, a
total of 24 formed the basis of the review. More than 40 per cent of the publications
referred to the Multiple Sclerosis Risk Sharing Scheme implemented in the UK
since 2002. The review did not identify any cost benefit analysis evaluating the
overall economic impact of schemes in monetary terms. All studies discussed costs
and benefits qualitatively and in some cases, when known, some costs were re-
ported. Schemes’ key stakeholders – health service employees, companies, regu-
lators –bear different costs and benefits and conflicting incentives may arise. Costs
and benefits widely vary depending on the characteristics of the scheme.
CONCLUSIONS: There is lack of consensus on the welfare consequences of the
schemes and their social desirability. Identified benefits are countered by signifi-
cant costs and the overall balance remains unclear. Further research is necessary:
a) to assess in a transparent way to what extent the transactional costs and admin-
istrative burden are shared between payers and pharmaceutical companies, as
they constitute an important barrier for the implementation of the schemes, and b)
to aid design of a successful Value Based Pricing system for new medicines in the
UK, given the similar principles that underpin outcome-based schemes where
prices are set to match “real world” NHS value in practice.
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OBJECTIVES: It is widely recognised that the National Institute for Health and
Clinical Excellence (NICE) in the UK employs cost-effectiveness thresholds in
health technology appraisal decision-making. This incremental cost-effectiveness
ratio (ICER) threshold has been topic of much debate and is estimated to lie around
£30,000 per quality-adjusted life-year (QALY) gained. In December 2008, NICE ap-
proved supplementary advice to reconsider this threshold for life-extending, end-
of-life interventions. This policy applies to treatments indicated for small patient
populations with life expectancies of usually under 24 months, that typically pro-
long survival by at least 3 months. The aim of this study was to explore NICE’s
increased ICER threshold when end-of-life conditions are taken into account.
METHODS: All NICE technology appraisals issued between December 2008 and
June 2011 were reviewed. The appraisals in which end-of-life considerations ap-
plied were identified and ICERs from these appraisals were extracted. RESULTS: In
total, 53 single technology appraisals were published in the timeframe considered;
of these, only 13 fulfilled the end-of-life criteria, all concerning treatments for
cancer. The final ICERs of these 13 interventions ranged from £31,800 to £68,000,
although 10 out of 13 manufacturers employed patient access schemes to lower
these values. Both the highest ICER that was approved and the lowest ICER that was
not approved were £49,300 per QALY gained. Interestingly, both of these appraisals
concerned interventions for the treatment of advanced renal cell carcinoma, im-
plying that other factors must have been taken into account by NICE to reach this
judgement. CONCLUSIONS: Cost-effectiveness seems to be the most important
criterion for NICE in their health technology appraisals. For end-of-life, life-extend-
ing treatments, the cost-effectiveness threshold appears to lie around £50,000 per
QALY. However, review of individual appraisals shows that other factors such as
uncertainty in the estimates and unmet need are also taken into account in NICE’s
decision-making.
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OBJECTIVES: In Europe, Health Technology Assessment (HTA) bodies produce cov-
erage decisions that guide public funding of pharmaceuticals. This analysis exam-
ines and weights those factors that drive HTA coverage decisions, focusing on the
National Institute for Health and Clinical Excellence (NICE) in England and Wales,
the Scottish Medicines Consortium (SMC), the Dutch College voor Zorgverzekerin-
gen (CVZ), and the French Haute Autorité de Sante (HAS). METHODS: A dataset of
approximately 1000 HTA coverage decisions by NICE, SMC, CVZ and HAS from the
period 2004-2009 was created, containing more than 30 clinical, economic, process
and socio-economic factors extracted from published HTA reports. A three-cate-
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